Clinical trial considerations on male contraception and collection of pregnancy information from female partners

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Banholzer, Maria L ^a   Buergin, Heinrich ^a   Wandel, Christoph ^a   Schmitt, Georg ^a   Gocke, Elmar ^a   Peck, Richard ^c   Singer, Thomas ^a   Reynolds, Theresa ^d   Mannino, Marie ^b   Deutsch, Jonathan ^e   Doessegger, Lucette ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d GENENTECH INC   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Genotoxicity; Male contraception; Paternal exposure; Teratogenicity

Indexed keywords

IMMUNOGLOBULIN;

ACCESS TO INFORMATION; AREA UNDER THE CURVE; ARTICLE; CONCEPTION; CONDOM; CONTRACEPTION; CONTROLLED STUDY; EMBRYO DEVELOPMENT; EMBRYOTOXICITY; FEMALE; FETOTOXICITY; GENOTOXICITY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA HALF LIFE; PREGNANCY; PREGNANT WOMAN; PROGENY; RISK REDUCTION; SEMINAL PLASMA; TERATOGENICITY; TOXICITY TESTING; CLINICAL TRIAL (TOPIC); DECISION TREE; INFORMATION PROCESSING; SEXUALITY; STATISTICS;

CLINICAL TRIALS AS TOPIC; CONDOMS; CONTRACEPTION; DATA COLLECTION; DECISION TREES; FEMALE; HUMANS; MALE; PREGNANCY; SEXUAL PARTNERS;

EID: 84865382745     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-129     Document Type: Article

References (33)

1. Dicke JM. Teratology: Principles and practice. Med Clin North Am 1989, 73:567-582.
2. O'Rahilly R, Müller F. Human embryology and teratolog 2001, Wiley-Liss, New York, New York.
3. EMEA/CHMP/313666/2005 Committee for medicinal products for human use (CHMP): guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data 2005, EMEA/CHMP/313666/2005.
4. Klemmt L, Scialli AR. The transport of chemicals in semen. Birth Defects Res B Dev Reprod Toxicol 2005, 74:119-131. 10.1002/bdrb.20031, 15834901.
5. Yazigi RA, Odem RR, Polakoski KL. Demonstration of specific binding of cocaine to human spermatozoa. JAMA 1991, 266:1956-1959. 10.1001/jama.1991.03470140068026, 1895473.
6. Ames BN, Lee FD, Durston WE. An improved bacterial test system for the detection and classification of mutagens and carcinogens. Proc Natl Acad Sci U S A 1973, 70:782-786. 10.1073/pnas.70.3.782, 433358, 4577135.
7. McCann J, Spingarn NE, Kobori J, Ames BN. Detection of carcinogens as mutagens: Bacterial tester strains with R factor plasmids. Proc Natl Acad Sci U S A 1975, 72:979-983. 10.1073/pnas.72.3.979, 432447, 165497.
8. McCann J, Choi E, Yamasaki E, Ames BN. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc Natl Acad Sci U S A 1975, 72:5135-5139. 10.1073/pnas.72.12.5135, 388891, 1061098.
9. Lee BH, Lee SJ. in vitro chromosome aberration assay using human bronchial epithelial cells. J Toxicol Environ Health A 1998, 55:325-329. 10.1080/009841098158377, 9829556.
10. Chen T, Moore MM. Optimization in Drug Discovery: In Vitro Methods 2004, 337-352. Humana Press, Totowa, Yan Z, Caldwell GW.
11. Schmid W. The micronucleus test. Mutat Res 1975, 31:9-15. 10.1016/0165-1161(75)90058-8, 48190.
12. Tometsko AM, Torous DK, Dertinger SD. Analysis of micronucleated cells by flow cytometry. 1. Achieving high resolution with a malaria model. Mutat Res 1993, 292:129-135. 10.1016/0165-1161(93)90140-U, 7692249.
13. Speit G, Hartmann A. The comet assay: A sensitive genotoxicity test for the detection of DNA damage and repair. Methods Mol Biol 2006, 314:275-286. 10.1385/1-59259-973-7:275, 16673888.
14. ICH Harmonised Tripartite Guideline Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use 2009, ICH Harmonised Tripartite Guideline.
15. ICH Harmonised Tripartite Guideline S6 Preclinical safety evaluation of biotechnology-derived pharmaceuticals. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use 1997, ICH Harmonised Tripartite Guideline S6.
16. Addendum to ICH S6 Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6(R1): Current step 2 version. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use 2009, Addendum to ICH S6.
17. Reviewer Guidance Integration of study results to assess concerns about human reproductive and developmental toxicities. US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER). Pharmacology/Toxicology 2001, Reviewer Guidance.
18. Rules governing medicinal products in the EU - Guidelines on Pharmacovigilance for Medicinal Products for Human Use - Volume 9A 2009,
19. CPMP/ICH/291/95 ICH Topic E 8 General Considerations for Clinical Trials. Note for guidance on general considerations for clinical trials 1995, CPMP/ICH/291/95.
20. MHRA Medical Guidance Clarification of contraceptive wording in clinical trials 2009, MHRA Medical Guidance.
21. ICH E3C Post approval safety data management and standard for expedited reporting 2003, ICH E3C.
22. Reviewer Guidance Evaluating the risks of drug exposure in human pregnancies U.S. Department of Health and Human Services; Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), April 2005; Clinical/Medical 2005, 2837687, 20228306, Reviewer Guidance.
23. Guidance for Industry Establishing pregnancy exposure registries. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER), August 2002; Clinical/Medical 2002, Guidance for Industry.
24. Food and Drug Administration Office of Women's Health. Birth control guide 2007, Food and Drug Administration.
25. Moldoveanu Z, Huand W-Q, Kulhavy R, Pate MS, Mestecky J. Human Male Genital Tract Secretions: Both Mucosal and Systemic Immune Compartments Contribute to the Humoral Immunity. J Immunol 2005, 175:4127-4136.
26. Kuo PY, Sherwood JK, Saltzman WM. Topical antibody delivery systems produce sustained levels in mucosal tissue and blood. Nat Biotechnol 1998, 16:163-167. 10.1038/nbt0298-163, 9487523.
27. Sherwood JK, Zeitlin L, Chen X, Whaley KJ, Cone RA, Saltzman WM. Residence half-life of IgG administered topically to mouse vagina. Biol Reprod 1996, 54:264-269. 10.1095/biolreprod54.1.264, 8838025.
28. Chen N, Lau H, Choudhury S, Wang X, Assaf M, Laskin OL. Distribution of lenalidomide into semen of healthy men after multiple oral doses. J Clin Pharmacol 2010, 50:767-774. 10.1177/0091270009355157, 20160158.
29. EMEA/CHMP/SWP/28367/07 Committee for medicinal products for human use (CHMP): Guideline on strategies to identify and mitigate risks for first-inhuman clinical trials with investigational medicinal products 2007, EMEA/CHMP/SWP/28367/07.
30. Amann RP. The cycle of the seminiferous epithelium in humans: a need to revisit?. J Androl 2008, 29:469-487. 10.2164/jandrol.107.004655, 18497337.
31. M3 (R2) Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals 2009, M3 (R2).
32. Roche Laboratories Inc Accutane(R) prescribing information 2008, Roche Laboratories Inc.
33. ICH S1A Guideline Guideline on the need for carcinogenicity studies of pharmaceuticals. ICH S1A Guideline: Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals 1995, ICH S1A Guideline.